NPIC
PCRX icon

Neumeier Poma Investment Counsel’s Pacira BioSciences PCRX Stock Holding History

Neumeier Poma Investment Counsel’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-151,810
Closed -$4.44M – 45
2024
Q1 		$4.44M Sell
151,810
-15,360
-9% -$472K 0.41% 40
2023
Q4 		$5.64M Sell
167,170
-98,450
-37% -$2.88M 0.5% 39
2023
Q3 		$8.15M Buy
265,620
+15,700
+6% +$566K 0.8% 40
2023
Q2 		$10M Sell
249,920
-7,600
-3% -$314K 0.92% 38
2023
Q1 		$10.5M Sell
257,520
-19,070
-7% -$759K 0.98% 38
2022
Q4 		$10.7M Buy
276,590
+12,275
+5% +$597K 0.99% 40
2022
Q3 		$14.1M Sell
264,315
-85,385
-24% -$4.75M 1.39% 32
2022
Q2 		$20.4M Buy
349,700
+32,275
+10% +$2.11M 1.59% 31
2022
Q1 		$24.2M Sell
317,425
-10,425
-3% -$695K 1.63% 32
2021
Q4 		$19.7M Sell
327,850
-294,250
-47% -$16.2M 1.1% 36
2021
Q3 		$34.8M Sell
622,100
-24,430
-4% -$1.41M 2.07% 28
2021
Q2 		$39.2M Buy
646,530
+43,670
+7% +$2.76M 2.3% 19
2021
Q1 		$42.3M Buy
602,860
+5,715
+1% +$408K 2.54% 16
2020
Q4 		$35.7M Buy
597,145
+165,445
+38% +$9.69M 2.37% 19
2020
Q3 		$26M Buy
+431,700
New +$25.1M 2.14% 21

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neumeier Poma Investment Counsel's PCRX Position: Q2 2024 in Review

Neumeier Poma Investment Counsel sold out of Pacira BioSciences (PCRX) in Q2 2024, closing a stake of 151,810 shares — an estimated $4.44M sold.

Neumeier Poma Investment Counsel first reported a position in PCRX in Q3 2020 and held it in 15 quarters. The position peaked at $42.3M in Q1 2021. 281 funds tracked by Wall St. Rank hold PCRX as of Q2 2024.

  • Neumeier Poma Investment Counsel reported no remaining Pacira BioSciences position as of Q2 2024 after selling out during the quarter.
  • Neumeier Poma Investment Counsel sold 151,810 Pacira BioSciences shares in Q2 2024, an estimated $4.44M.
  • Neumeier Poma Investment Counsel first reported a position in Pacira BioSciences in Q3 2020 and held it in 15 quarters.
  • Neumeier Poma Investment Counsel's Pacira BioSciences position peaked at $42.3M in Q1 2021.
  • 281 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2024.

Based on Neumeier Poma Investment Counsel's 13F filing for Q2 2024, filed 13 Aug 2024.